The Ministry of Health, Labor, and Welfare (MHLW) in Japan has granted Orphan Drug Designation (ODD) to Lundbeck's investigational drug, amlenetug, a potential new treatment option targeting Multiple ...
Montpellier, France Monday, March 10, 2025, 15:00 Hrs [IST] ...
Positive results from the pivotal ADEPT phase 2/3 study evaluating the investigational use of Dupixent (dupilumab) in adults with moderate-to-severe bullous pemphigoid (BP) were shared in a ...
Over-Year, and Generated PEDMARK ® Q4 2024 Net Product Sales of $7.9 Million ~ ~ Delivered Q4 2024 EBITDA Loss of $0.6 Million and Company Has $26.6 Million in Cash, Cash Equivalents and Short-Term ...
Production in Okinawa, Japan to be the first in Asia Pacific, targeting 200 million liters of ETJ SAF annually ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback